Sanofi/GSK restart COVID-19 vaccine trials after tweaking formulation
pharmaphorum
FEBRUARY 22, 2021
The vaccine is based around an adjuvanted recombinant protein, which will be tested in a new phase 2 study to assess the response including in older adults. Regulators in the US and UK are reviewing data from another vaccine from Novavax.
Let's personalize your content